-
Tianyao Pharmaceutical's adrenaline hydrochloride injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
In November 2019, Jinyao Pharmaceutical submitted a supplementary application for consistency evaluation to the Drug Evaluation Center of the National Medical Products Administration and was accepted .
-
GlaxoSmithKline's PD-1 inhibitor Jemperli is approved by the UK
Time of Update: 2021-06-17
Jemperli is a PD-1 blocking antibody, specifically suitable for: recurrence of disease progression, mismatch repair defect (dMMR)/high degree of microsatellite instability (MSI-H) during or after treatment with platinum-containing chemotherapy Patients with sexual or advanced endometrial cancer .
-
Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.S. FDA
Time of Update: 2021-06-17
The press release stated that this is the first approved vaccine against 20 pneumococcal serotypes that cause most aggressive diseases and pneumonia, including 7 serotypes that cause 40% of pneumococcal disease cases and deaths in the United States .
-
The State Food and Drug Administration issued an announcement on the cancellation of the medical device registration certificate
Time of Update: 2021-06-17
Medical Network News, June 10, June 9th, the State Food and Drug Administration issued an announcement, in accordance with the "Medical Device Registration Management Measures", according to the enterprise application, the registration number of Nikon Corporation is now cancelled: National Machinery Injection 20172226595, Product name: Medical device registration certificate for biological microscope .
-
"Nature": The spread of new coronavirus variants in Europe is related to travel
Time of Update: 2021-06-16
The study pointed out that this new variant 20E (EU1) new coronavirus, which is believed to have appeared in Spain, has been introduced to European countries hundreds of times by summer travelers .
-
Hengrui Medicine's Carrelizumab was approved for the world's first first-line nasopharyngeal cancer indication
Time of Update: 2021-06-16
Recently, the PD-1 inhibitor Carrelizumab (Erica®) independently developed by Hengrui Medicine has officially obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), approving Carrelizumab Monoclonal antibody combined with cisplatin and gemcitabine is used for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
-
Luye Pharma’s new antidepressant drug Ansufaxine Hydrochloride Sustained-Release Tablets was accepted by CDE
Time of Update: 2021-06-16
On June 10th, Luye Pharmaceutical Group announced that its self-developed Chinese chemical drug Class 1 new drug Ansufacine Hydrochloride Sustained-Release Tablets (LY03005) has been officially accepted by the Drug Evaluation Center of the China National Medical Products Administration .
-
Teva again initiates patent lawsuit against Eli Lilly over migraine drug Emgality
Time of Update: 2021-06-16
Up to now, there have been three monoclonal antibody migraine preventive drugs that target CGRP or its receptors: Novartis and Amgen Aimovig, Eli Lilly Emgality and Teva Ajovy .
-
my country's 21 new crown vaccines enter clinical trials
Time of Update: 2021-06-16
Relevant departments pay close attention to virus mutations and other issues my country's 21 new crown vaccines have entered the clinical trial stage.
-
More WHO research finds to rewrite the timeline of the new crown epidemic
Time of Update: 2021-06-16
In December last year, another group of researchers from the University of Milan reported in the US "Journal of New Infectious Diseases" that a 4-year-old boy's oropharyngeal swab sample collected on December 5, 2019 tested positive for the new crown virus .
-
The application status of new solid dosage forms for oral administration in children
Time of Update: 2021-06-16
Children's oral solid preparations in China are relatively simple, mostly ordinary tablets, followed by dispersible tablets and sustained-release tablets, and the rest of the tablets account for only 10%.
-
New coronavirus vaccination status: 80,896,200 doses!
Time of Update: 2021-06-16
New coronavirus vaccination status: 80,896,200 doses!
New coronavirus vaccination status: 80,896,200 doses!
New coronavirus vaccination status: 80,896,200 doses!
As of June 8, 2021, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps have reported a total of 80,8962,000 doses of new coronavirus vaccine .
-
Hengrui Pharmaceuticals Carrelizumab Approved for First-line Treatment of Nasopharyngeal Carcinoma
Time of Update: 2021-06-16
According to Hengrui Medicine, the approval of the new indication of Carrelizumab is based on the CAPTAIN-1ST study .
At the just-concluded 2021ASCO annual meeting, Hengrui Medicine and Junshi Bio-PD-1 inhibitors both announced numerous research progress .
-
Shi Yi: To do scientific research is to face the major strategic needs of the country
Time of Update: 2021-06-16
" Shi Yi said: "The so-called research period means that when emergencies occur, we must gather forces in a short time and quickly produce scientific research results .
-
Yangtze River will win $3 billion in oral hypoglycemic drugs!
Time of Update: 2021-06-16
According to data from Meinenet, in 2020, the total sales of sitagliptin tablets in the terminals of public medical institutions in China and physical pharmacies in Chinese cities will exceed 1.
-
AstraZeneca's new crown vaccine is linked to slightly increased risk of bleeding disorders
Time of Update: 2021-06-16
At 23:00 on June 9th, Beijing time, the top international academic journal "Nature Medicine" (Nature Medicine) published online a study completed by the British team, entitled "First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic" , thromboembolic and hemorrhagic events in Scotland" .
-
Qilu enters the market with annual sales of $1.9 billion blockbuster drugs and Chengdu Beite competes for the first imitation
Time of Update: 2021-06-16
Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval .
-
China Disease Control: The best way to prevent new coronary pneumonia is to get vaccinated
Time of Update: 2021-06-16
Medium disease control: the best way to prevent new coronary pneumonia is still vaccination At a press conference held by the Joint Prevention and Control Mechanism of the State Council today (11th) , Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, said in response to questions about the effectiveness of vaccine protection that the best way to prevent new coronary pneumonia is to get vaccinated .
-
People aged 3-17 can use inactivated new coronavirus vaccine urgently
Time of Update: 2021-06-16
Cui Gang, the second-level inspector of the CDC of the National Health Commission , introduced at the press conference of the Joint Prevention and Control Mechanism of the State Council on the 11th that at present, China's new crown virus vaccination is mainly carried out for people over 18 years old, and the relevant state departments have approved 3- 17-year-olds can start emergency use of the new coronavirus inactivated vaccine .
-
CSPC's new anti-tumor nano drug was approved for clinical use
Time of Update: 2021-06-16
On June 10, CSPC issued an announcement stating that the new anti-tumor nano-drug "Sirolimus for injection (albumin-binding)" developed by Sinoqi Pharmaceutical, a subsidiary of the company, had been approved for clinical trials in China .
